Remy Luthringer Ph.D.
Net Worth
Last updated:
What is Remy Luthringer Ph.D. net worth?
The estimated net worth of Dr. Remy Luthringer Ph.D. is at least $7,066,225 as of 2 May 2023. He owns shares worth $158,686 as insider, has earned $105,139 from insider trading and has received compensation worth at least $6,802,400 in Minerva Neurosciences, Inc..
What is the salary of Remy Luthringer Ph.D.?
Dr. Remy Luthringer Ph.D. salary is $850,300 per year as Executive Chairman & Chief Executive Officer in Minerva Neurosciences, Inc..
How old is Remy Luthringer Ph.D.?
Dr. Remy Luthringer Ph.D. is 64 years old, born in 1961.
What stocks does Remy Luthringer Ph.D. currently own?
As insider, Dr. Remy Luthringer Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | Executive Chairman & Chief Executive Officer | 68,994 | $2.3 | $158,686 |
What does Minerva Neurosciences, Inc. do?
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Remy Luthringer Ph.D. insider trading
Minerva Neurosciences, Inc.
Dr. Remy Luthringer Ph.D. has made 8 insider trades between 2017-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,641 units of NERV stock worth $13,690 on 2 May 2023.
The largest trade he's ever made was exercising 32,096 units of NERV stock on 3 Feb 2017. As of 2 May 2023 he still owns at least 68,994 units of NERV stock.
Minerva Neurosciences key executives
Minerva Neurosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Jay B. Saoud Ph.D. (66) Consultant
- Dr. Remy Luthringer Ph.D. (64) Executive Chairman & Chief Executive Officer
- Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA (64) Pres